legal research FAQ

You must submit an IND application to the FDA before administering Semax amidate to any human subject. The IND requires preclinical toxicology studies in at least two animal species, manufacturing documentation proving GMP compliance, a detailed clinical protocol with inclusion/exclusion criteria, and investigator qualifications. Budget at minimum two million dollars for preclinical work and six to twelve months for FDA review before enrolling the first participant. Institutional IRB approval is also required, but it's secondary to IND authorization.

Marketing Selank Amidate as a supplement with cognitive benefits is illegal and triggers immediate FDA enforcement. Supplements are regulated under the Dietary Supplement Health and Education Act (DSHEA), which applies only to vitamins, minerals, herbs, and amino acids. Not synthetic peptides. Selank Amidate is a synthetic analog of tuftsin, not a dietary ingredient, which disqualifies it from supplement classification. Any supplier making cognitive or anxiolytic claims about Selank Amidate is marketing an unapproved new drug and will receive an FDA Warning Letter demanding immediate cessation of sales and corrective action.

Avoid that supplier—ambiguous legal language signals either regulatory ignorance or intentional evasion. Compliant suppliers explicitly state 'for research use only' or 'not for human consumption' on every product page, in checkout confirmation emails, and on shipping labels. The phrase 'not illegal' is marketing speak designed to attract buyers seeking off-label use while avoiding explicit health claims. PE-22-28 legal compliance is not about what's technically 'not illegal'—it's about what's affirmatively compliant with FDA labeling and marketing requirements. Research institutions should establish vendor qualification criteria that require explicit research-only labeling. Purchasing departments often approve suppliers based on price and availability without evaluating regulatory posture. Labs should request that procurement offices add FDA compliance language to vendor qualification checklists—ensuring that every peptide supplier used by the institution operates within the same legal framework that governs the research itself.

Physicians can legally prescribe off-label compounds under their medical license authority, but Pinealon isn't an FDA-approved drug or a recognized compounding ingredient in USP standards. A doctor writing a prescription doesn't make the compound legal for human use—it just shifts liability. The compounding pharmacy filling that prescription would need to source Pinealon from a registered supplier and prepare it under sterile conditions meeting state pharmacy board requirements, but without FDA approval as an API, most licensed compounders won't touch it. If they do, both prescriber and pharmacy operate in regulatory gray area where state medical boards and pharmacy boards could take action if adverse events occur. Our peptides at Real Peptides are explicitly not for prescription compounding—they're synthesized for laboratory research, not clinical pharmacy preparation.

File an Investigational New Drug (IND) application with the FDA before administering PE-22-28 to any human participant. Research involving human subjects requires FDA approval regardless of whether the study is funded, whether participants are compensated, or whether the peptide is administered in a clinical or academic setting. The IND process includes submitting preclinical data (animal studies, toxicology reports), manufacturing information (supplier credentials, purity data), and a detailed clinical protocol reviewed by an institutional review board (IRB). Operating a human trial without an approved IND is a federal violation that can result in criminal charges, institutional funding loss, and permanent disqualification from NIH grants. In 2022, the FDA shut down an academic study involving an unapproved peptide after discovering the principal investigator had bypassed the IND process—believing the peptide's research-grade status exempted the study from oversight. It did not. PE-22-28 legal use in human research is possible, but only through the formal IND pathway.

Do not purchase from that supplier—they are violating FDA regulations regardless of the disclaimer label. Dosing guides, injection instructions, or 'cycle' protocols imply human therapeutic use, which converts the peptide into an unapproved drug subject to enforcement action. The FDA evaluates a supplier's overall marketing and sales practices, not just the fine print on the label. In a 2024 enforcement sweep, the agency issued warning letters to peptide vendors whose websites included research disclaimers on product pages but featured testimonials, dosing calculators, and before-and-after photos elsewhere on the site—the totality of the marketing negated the legal protection of the disclaimer. Research institutions should audit supplier websites before procurement. If the site sells peptide stacks alongside standalone compounds, offers 'beginner,' 'intermediate,' and 'advanced' product tiers, or includes FAQ sections addressing 'how much should I take' or 'when will I see results,' those are red flags. Compliant suppliers limit content to technical specifications, storage guidelines, and reconstitution chemistry—never therapeutic guidance.

You can legally purchase research-grade Pinealon as an individual, but your declared intent determines compliance. If you attest it's for personal laboratory work—such as analytical chemistry, biochemical assays, or educational purposes—and you don't administer it to yourself or others, the purchase is legally defensible under research use provisions. However, if you order with intent to self-administer, you're using an unapproved drug outside medical or clinical trial oversight, which violates 21 USC 355 even if enforcement is rare. Personal liability increases if you experience adverse effects, because you have no prescriber oversight, no pharmaceutical-grade purity verification, and no legal standing to claim the product caused harm through off-label misuse.

If the DEA were to schedule Pinealon or if the FDA issued explicit enforcement guidance reclassifying it as a prohibited compound, all current legal procurement pathways would close immediately. Possession, sale, and distribution would become federal offenses with criminal penalties. This happened with analogs of some nootropic compounds when the DEA invoked the Federal Analogue Act to prosecute vendors. As of 2026, Pinealon doesn't appear on any federal controlled substance schedules, and it lacks the structural characteristics that typically trigger analogue enforcement (it's not an opioid receptor agonist, stimulant, or cannabinoid analog). The risk of sudden scheduling is low, but not zero—peptides with human performance or cognitive enhancement claims draw more regulatory scrutiny than compounds with narrow research applications.

You can legally procure and use Pinealon in laboratory settings under institutional compliance frameworks. Your IRB and research compliance office will require documentation proving the peptide is sourced from a legitimate supplier, stored under proper conditions (typically 2–8°C for lyophilized powder, −20°C for long-term storage), and used exclusively in approved in vitro or animal model protocols. If your study involves human subjects, you need an active IND application submitted to the FDA and IRB approval confirming the trial design meets ethical and safety standards—buying research-grade peptides from non-pharma suppliers won't meet those requirements. Clinical-grade peptides for human trials must come from FDA-registered manufacturers with cGMP certification, which research suppliers like Real Peptides don't provide because our compounds serve non-clinical laboratory applications.

Store the peptide according to manufacturer specifications and document the reason for non-use in laboratory records. Unused research chemicals do not require disposal unless they pose a safety hazard or the institution's chemical inventory policy mandates it. PE-22-28 stored at −20°C as lyophilized powder remains stable for 24–36 months, so canceled protocols do not create immediate disposal obligations. However, labs should not transfer unused peptides to other researchers without updating institutional procurement and protocol records—untracked transfers create compliance gaps if audited. If the peptide cannot be repurposed for another approved protocol, dispose of it according to institutional chemical waste procedures. Many universities classify synthetic peptides as biohazardous waste requiring incineration rather than standard chemical disposal. PE-22-28 legal handling extends to disposal—improper disposal that allows diversion to non-research use could expose the institution to liability.

Secure institutional review board (IRB) approval if your research involves animal subjects. Purchase DSIP only from suppliers who provide certificate of analysis documentation showing peptide purity ≥98% and proper amino acid sequencing. Your institution's procurement office should verify the supplier is a registered business entity operating within regulatory compliance frameworks. Most universities require researchers to document that research-grade compounds are labeled "Not for Human Consumption" and are acquired through legitimate scientific supply channels.

Verify import regulations for your country before placing the order. U.S. researchers must ensure the supplier provides commercial invoice documentation clearly stating the product is for research use, includes the correct Harmonized Tariff Schedule (HTS) code for peptides, and ships with appropriate customs declarations. If the supplier cannot provide these documents, the shipment risks seizure at customs. Research peptides entering Australia or Canada require advance import permits. Ordering without this documentation guarantees confiscation and potential legal consequences.

You are violating the legal framework under which the peptide was sold and assuming significant personal risk. Research-grade peptides are not manufactured under the same sterility, purity, and quality control standards as FDA-approved medications. Self-administration of DSIP carries unknown contamination risks, incorrect dosing risks due to variable purity between batches, and zero medical oversight for adverse events. The legal risk is substantial. You're using an unapproved drug for human consumption, which violates federal law even if you purchased it legally for research purposes.

That claim misrepresents the regulatory framework. The fact that DSIP is not a controlled substance under the DEA does not mean it's legal for human consumption. Those are separate legal questions. FDA regulations prohibit the sale of unapproved drugs for human use regardless of DEA scheduling status. A supplier making this claim is either ignorant of pharmaceutical law or deliberately misleading customers. Both scenarios should trigger immediate concern about the supplier's legitimacy and product quality.

You are violating federal law. The moment an unapproved compound is administered to a human outside an FDA-authorized clinical trial, it becomes an investigational new drug used without IND exemption. A violation of the Federal Food, Drug, and Cosmetic Act. The FDA rarely prosecutes individuals for personal use of research peptides, but prosecution is possible, and the legal risk extends to anyone who provided the compound if they knew or should have known it would be used for human consumption. Suppliers who market peptides with dosing instructions or therapeutic claims are complicit in this violation and face significantly higher enforcement risk.

You are operating in a legal gray zone. Federal law permits individuals to purchase research chemicals for qualified research use, but 'qualified' typically implies affiliation with an accredited institution or documentation of a legitimate research protocol. If you purchase SS-LUP-332 from a compliant supplier, label it correctly, and do not administer it to yourself or others, possession is not explicitly illegal. However, if questioned by authorities, you would need to demonstrate research intent. And the absence of institutional backing weakens that claim. The practical risk is low for possession alone, but the legal standing is vulnerable if the compound is used for self-administration.

Customs seizures of research peptides occur when documentation is missing, labeling is ambiguous, or the shipment originates from a non-compliant source. If your shipment included a certificate of analysis, research-use-only labeling, and was sent by a registered supplier, you can typically contest the seizure by providing evidence of research intent and supplier compliance. If the shipment lacked documentation or came from an overseas gray-market vendor, recovery is unlikely, and you may receive a warning letter from Customs and Border Protection. Repeated seizures can trigger further investigation. To avoid this, source SS-LUP-332 domestically from FDA-registered suppliers whenever possible.